Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Subscribe and save 15% monthly on this essential supplement for people needing maintenance
The Phase 3 ophthalmic program (RGN-259) comprises three completed dry-eye trials (ARISE-1 n=317, ARISE-2 n=601, ARISE-3 n=700) and one completed European neurotrophic keratopathy trial (SEER-3), all of which missed their pre-specified primary endpoints
Supports healing and recovery at the muscular and cellular level
6d, 7d)
US$ 21.61
.jpeg)
US$ 21.34
US$ 21.28
US$ 25.84
US$ 28.78
